On 9 July 2025, Lupin Limited and Zentiva Group announced that they have entered into a global licence and supply agreement for the commercialisation of Lupin’s certolizumab pegol biosimilar referencing UCB’s Cimzia®.
Under the agreement, Lupin is responsible for development, manufacturing and supply, with split responsibility for commercialisation: Lupin will commercialise in the US and Canada, with Zentiva in ROW, predominantly Europe and CIS markets. Lupin will receive an initial payment of USD 10m and up to a further USD 50m on achievement of regulatory milestones, with profits from the defined markets to be shared by the companies.
Alvotech also has a certolizumab pegol biosimilar in development, AVT10, which it acquired from Xbrane in June 2025. In early July 2025, Alvotech and Advanz Pharma entered a European supply and commercialisation agreement for AVT10.